US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SDEV
$7.48
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Recor Medical
Recor Medical Announces AMA CPT Editorial Panel Approval of Two New Category I CPT® Codes for Renal Denervation
October 01, 2026
From
Recor Medical
Via
GlobeNewswire
Recor Medical Names Dr. Helen Reeve-Stoffer Chief Executive Officer
August 04, 2026
From
Recor Medical
Via
GlobeNewswire
Recor Medical Highlights Innovation and Global Action on World Hypertension Day 2026
May 15, 2026
From
Recor Medical
Via
GlobeNewswire
Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 months with Recor Medical’s Paradise Ultrasound Renal Denervation System
October 30, 2025
From
Recor Medical
Via
GlobeNewswire
CMS Issues National Coverage Determination for Recor Medical’s Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
October 28, 2025
From
Recor Medical
Via
GlobeNewswire
Recor Medical Announces Paradise Ultrasound Renal Denervation System Receives Manufacturing and Marketing Approval in Japan for the Treatment of Resistant Hypertension
August 25, 2025
From
Recor Medical
Via
GlobeNewswire
Recor Medical Responds to the American Heart Association (AHA) and American College of Cardiology’s (ACC) Updated Guidelines on Renal Denervation for the Treatment of Hypertension
August 15, 2025
From
Recor Medical
Via
GlobeNewswire
Recor Medical Supports Proposed CMS National Coverage Determination of Renal Denervation for the Treatment of Hypertension
July 10, 2025
From
Recor Medical
Via
GlobeNewswire
Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
May 16, 2025
From
Recor Medical
Via
GlobeNewswire
Recor Medical Statement on CMS National Coverage Analysis of Renal Denervation for the Treatment of Hypertension
January 13, 2025
From
Recor Medical
Via
GlobeNewswire
Recor Medical announces CMS Grant of Transitional Pass-Through (TPT) Payment for Recor’s Paradise Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension
November 01, 2024
From
Recor Medical
Via
GlobeNewswire
Recor Medical Responds to the American Heart Association’s (AHA) Scientific Statement on Renal Denervation for the Treatment of Hypertension
August 19, 2024
From
Recor Medical
Via
GlobeNewswire
CMS Approves Additional Payment for Recor Medical’s Paradise™ Ultrasound Renal Denervation System in Hospital Inpatient Cases
August 12, 2024
From
Recor Medical
Via
GlobeNewswire
First Patients Treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS) for the Treatment of Uncontrolled Hypertension with Ultrasound Renal Denervation
July 25, 2024
From
Recor Medical
Via
GlobeNewswire
Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
May 17, 2024
From
Recor Medical
Via
GlobeNewswire
Recor Medical Announces First Cases of Paradise Ultrasound Renal Denervation Therapy in the United Arab Emirates
April 18, 2024
From
Recor Medical
Via
GlobeNewswire
Recor Medical and Otsuka Medical Devices Announce Positive Vote from U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on the Paradise™ Ultrasound Renal Denervation System for the Treatment of Hypertension
August 22, 2023
From
Recor Medical
Via
Business Wire
